Searchable abstracts of presentations at key conferences on calcified tissues

ba0003pp99 | Cancer and bone: basic, translational and clinical | ECTS2014

Changes in bone mineral density and biochemical markers of bone turnover in postmenopausal women with breast cancer initiating aromatase inhibitors therapy

Luchavova Maria , Zimovjanova Martina , Zikan Vit , Pribylova Jana , Cabinakova Michaela , Petruzelka Lubos

Postmenopausal women with early stage hormone-receptor-positive breast cancer (EBC) are standardly treated with aromatase inhibitors (AIs). However, one side-effect of AIs treatment is a decrease in bone mineral density (BMD) and an increased risk of fracture. The objectives of this study were to examine: i) changes in bone formation (N-terminal propeptide of type I procollagen; PINP) and bone resorption (cross-linked C-telopeptides of bone type I collagen; CTX) markers, as we...

ba0004oc8 | (1) | ICCBH2015

Combination sclerostin antibody and zoledronic acid treatment outperforms either treatment alone in a mouse model of osteogenesis imperfecta

Munns Craig , Peacock Lauren , Mikulec Kathy , Kneissel Michaela , Kramer Ina , Cheng Tegan , Schindeler Aaron , Little David

Introduction: Bisphosphonate treatment in children with osteogenesis imperfecta reduces bone catabolism and relies on modelling to form new bone. An anabolic treatment, anti-sclerostin antibody (Anti-SOST Ab), is being investigated in clinical trials. We hypothesized that combined treatment may produce superior outcomes in OI.Methods: Female Col1a2 G610C mice and their wild type littermates (WT) were treated from week 5 to week 9 of life with either sali...

ba0001oc4.5 | Osteoblasts and osteocytes | ECTS2013

Mechanical loading increases the effect of sclerostin antibody treatment in a mouse model of high turnover osteoporosis

von Salis-Soglio Marcella , Kuhn Gisela , Kneissel Michaela , Muller Ralph

Sclerostin, a Wnt signaling antagonist encoded by the SOST gene, negatively regulates osteoblasts and inhibits bone formation. Mechanical loading, which induces bone formation, leads to a decrease in sclerostin levels. Recently, neutralizing antibodies against sclerostin were tested successfully for the treatment of osteoporosis in rodents. However, sclerostin is not the only signal involved in mechanotransduction. Therefore we investigated whether treatment with sclerostin an...

ba0003pp37 | Bone biomechanics and quality | ECTS2014

Bone matrix mineralization after sclerostin antibody treatment in a mouse model of osteogenesis imperfecta

Roschger Andreas , Roschger Paul , Kneissel Michaela , Rauch Frank

Children with osteogenesis imperfecta (OI) still suffer from frequent fractures, despite bisphosphonate treatment. Thus new therapeutic approaches are needed. Sclerostin is a protein that is thought to inhibit bone formation. Treatment with sclerostin antibodies (SclAB) increases bone mass in animal models and in clinical trials and may be a rational therapy for OI as well.Transgenic (TgOI) Col1a1Jrt/+ mice were gene...

ba0003lb4 | (1) | ECTS2014

History of cardiovascular events and risk factors for cardiovascular events among osteoporotic patients initiating strontium ranelate in the UK

Yu Jingbo , Tang Jackson , Li Zhiyi , Sazonov Vasilisa , Sajjan Shiva , Lion Michaela , O'Regan Christopher

Objective: To estimate the proportion of patients who experienced cardiovascular (CV) events or were at risk for CV events prior to initiation of strontium ranelate among osteoporotic (OP) patients.Methods: This was a retrospective database analysis using the Clinical Practice Research Datalink (CPRD) database. Patients were included if they had ≥1 prescription (Rx) of strontium from 9/1/2008 to 8/31/2013, were aged ≥50 years as of the index ...

ba0005cabs.oc3.4 | Oral Communications | ECTS2016

Anti-sclerostin treatment prevents multiple myeloma bone disease and reduces tumour burden

McDonald Michelle , Reagan Michaela , Terry Rachael , Pettitt Jessica , Le Lawrence , Mohanty Sindhu , Kramer Ina , Kneissel Michaela , Brooks Daniel , Cheng Tegan , Little David , Bouxsein Mary , Rosen Cliff , Ghobrial Irene , Croucher Peter

Multiple myeloma is characterized by extensive bone marrow tumour and destructive osteolytic lesions. Both increased bone resorption and suppressed bone formation result in lesions and pathological fractures. Anti-resorptive therapies prevent further bone loss but patients continue to fracture, arguing for new therapies which increase bone strength. Anti-Sclerostin (Anti-Scl) is a potent stimulator of bone formation, is currently in clinical trials for osteoporosis, however it...

ba0005p72 | Bone development/growth and fracture repair | ECTS2016

Sulfated hyaluronan improves bone defect healing in type 2 diabetic rats by increasing osteoblast function

Picke Ann-Kristin , Salbach-Hirsch Juliane , Hintze Vera , Rauner Martina , Moller Stephanie , Kascholke Christian , Hacker Michael C , Schulz-Siegmund Michaela , Schnabelrauch Matthias , Scharnweber Dieter , Hofbauer Lorenz C , Hofbauer Christine

Bone fractures of patients suffering from type 2 diabetes mellitus (T2DM) represent an emerging socioeconomic problem. Underling mechanisms are poorly understood and therapies are limited. Our previous studies have shown that sulfated hyaluronan (sHA3) suppresses osteoclast activity while supporting osteoblast function in vitro. Hence, we now investigated if sHA3 can improve the delayed fracture healing in rats with T2DM.Porous, cross-linked lactide-base...

ba0005oc5.3 | Risk factors for fracture, Pagets disease of bone and musle and bone | ECTS2016

Osteoprotegerin autoantibodies are independently associated with low hip bone mineral density and increased fracture risk in patients with ankylosing spondylitis

Hauser Barbara , Zhao Sizheng , Visconti Micaela R , Riches Philip L , Goodson Nicola J , Ralston Stuart H

Osteoporosis and vertebral fractures are recognised complications of ankylosing spondylitis (AS) but the underlying causes are incompletely understood. Osteoprotegerin (OPG) is a decoy receptor for RANK-L and inhibits osteoclastogenesis. We have previously demonstrated that antibodies to OPG (OPG-Ab) are associated with osteoporosis and increased bone turnover in patients with autoimmune diseases. The aim of this study was to determine whether OPG-Abs were detectable in AS pat...